Literature DB >> 31929985

Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma.

Kai-Qian Zhou1,2, Wei-Feng Liu1,2,3, Liu-Xiao Yang1,2, Yun-Fan Sun1,2,4, Jie Hu1,2,4, Fei-Yu Chen1,2, Cheng Zhou1,2, Xiang-Yu Zhang1,2, Yuan-Fei Peng1,2,4, Lei Yu1,2,4, Jian Zhou1,2,3,5, Jia Fan1,2,3,5, Zheng Wang1,2,4.   

Abstract

BACKGROUND: The role of osteopontin (OPN) in intrahepatic cholangiocarcinoma (ICC) remains controversial. This study aimed to explore the prognostic value of OPN in patients with ICC undergoing curative resection.
METHODS: Patients undergoing curative resection from 2005 to 2016 were identified for inclusion in this retrospective study. The expression level of OPN in tumors was measured in each of the 228 patients by immunohistochemistry. Circulating OPN in serum was tested in 124 patients by ELISA. Tumor volume was calculated according to preoperative imaging or operation record. Proliferation assay, wound healing assay, and invasion assay were performed to investigate the biological function.
RESULTS: Low expression of OPN in tissue was associated with lymph node metastasis (P=0.009) and shorter overall survival (OS) (P=0.001). A low level of circulating OPN/volume was associated with multiple tumors (P<0.001), vascular invasion (P=0.027), visceral peritoneal perforation (P=0.001), and lymph node metastasis (P=0.002). It was also able to predict the invasive behavior, lymph node metastasis, and early recurrence with the area under the receiver operating curve (AUC) of being 0.719, 0.708 and 0.622 respectively. Patients with a low level of circulating OPN/volume had shorter OS (P=0.028) and disease-free survival (DFS) (P=0.004) and could benefit from adjuvant chemotherapy (P=0.011). Compared with negative controlled cells, ICC cell lines, which expressed more OPN, showed a decelerated proliferation rate, the weaker ability of migration and invasion, while the opposite was true for the cells expressed less OPN. MMP1, MMP10, and CXCR4 were negatively regulated by OPN.
CONCLUSIONS: A low level of circulating OPN/volume could indicate aggressive characteristics, along with poor prognosis and efficacy of adjuvant chemotherapy in ICC patients. Over expression of OPN may inhibit phenotypes facilitating ICC metastasis by negatively regulating MMP1, MMP10, and CXCR4. 2019 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma (ICC); osteopontin (OPN); prognosis

Year:  2019        PMID: 31929985      PMCID: PMC6943027          DOI: 10.21037/hbsn.2019.03.14

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  55 in total

1.  Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.

Authors:  Sven H Loosen; Christoph Roderburg; Katja L Kauertz; Inês Pombeiro; Catherine Leyh; Fabian Benz; Mihael Vucur; Thomas Longerich; Alexander Koch; Till Braunschweig; Tom F Ulmer; Christoph Heidenhain; Frank Tacke; Marcel Binnebösel; Maximilian Schmeding; Christian Trautwein; Ulf P Neumann; Tom Luedde
Journal:  J Hepatol       Date:  2017-06-29       Impact factor: 25.083

2.  MMP1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma.

Authors:  Min Liu; Yi Hu; Mei-Fang Zhang; Kong-Jia Luo; Xiu-Ying Xie; Jing Wen; Jian-Hua Fu; Hong Yang
Journal:  Cancer Lett       Date:  2016-04-26       Impact factor: 8.679

3.  Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit.

Authors:  Akshat Saxena; Terence C Chua; Anik Sarkar; Francis Chu; David L Morris
Journal:  J Gastrointest Surg       Date:  2010-05-14       Impact factor: 3.452

4.  Plasma osteopontin in acute liver failure.

Authors:  Praveen Srungaram; Jody A Rule; He Jun Yuan; Andreas Reimold; Benny Dahl; Corron Sanders; William M Lee
Journal:  Cytokine       Date:  2015-03-21       Impact factor: 3.861

5.  Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.

Authors:  Sheng-Bin Peng; Xiaoyi Zhang; Donald Paul; Lisa M Kays; Wendy Gough; Julie Stewart; Mark T Uhlik; Qi Chen; Yu-Hua Hui; Maciej J Zamek-Gliszczynski; John A Wijsman; Kelly M Credille; Liang Zeng Yan
Journal:  Mol Cancer Ther       Date:  2014-12-12       Impact factor: 6.261

Review 6.  Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management.

Authors:  Han Zhang; Tian Yang; Mengchao Wu; Feng Shen
Journal:  Cancer Lett       Date:  2015-09-25       Impact factor: 8.679

7.  Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection.

Authors:  Biao Deng; Xiao-Fei Zhang; Xu-Chao Zhu; Hua Huang; Hu-Liang Jia; Qing-Hai Ye; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Oncol Rep       Date:  2013-09-19       Impact factor: 3.906

8.  Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer.

Authors:  Akira Yokoi; Yusuke Yoshioka; Yusuke Yamamoto; Mitsuya Ishikawa; Shun-Ichi Ikeda; Tomoyasu Kato; Tohru Kiyono; Fumitaka Takeshita; Hiroaki Kajiyama; Fumitaka Kikkawa; Takahiro Ochiya
Journal:  Nat Commun       Date:  2017-03-06       Impact factor: 14.919

9.  Osteopontin deficiency aggravates hepatic injury induced by ischemia-reperfusion in mice.

Authors:  S Patouraux; D Rousseau; A Rubio; S Bonnafous; V J Lavallard; J Lauron; M-C Saint-Paul; B Bailly-Maitre; A Tran; D Crenesse; P Gual
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

10.  Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin.

Authors:  Qiongzhu Dong; Xuchao Zhu; Chun Dai; Xiaofei Zhang; Xiaomei Gao; Jinwang Wei; Yuanyuan Sheng; Yan Zheng; Jian Yu; Lu Xie; Yi Qin; Peng Qiao; Chuang Zhou; Xinxin Yu; Huliang Jia; Ning Ren; Haijun Zhou; Qinghai Ye; Lunxiu Qin
Journal:  Oncotarget       Date:  2016-03-15
View more
  8 in total

Review 1.  Novel approaches in search for biomarkers of cholangiocarcinoma.

Authors:  Lavinia-Patricia Mocan; Maria Ilieș; Carmen Stanca Melincovici; Mihaela Spârchez; Rareș Crăciun; Iuliana Nenu; Adelina Horhat; Cristian Tefas; Zeno Spârchez; Cristina Adela Iuga; Tudor Mocan; Carmen Mihaela Mihu
Journal:  World J Gastroenterol       Date:  2022-04-21       Impact factor: 5.374

Review 2.  The Tumor Microenvironment in Cholangiocarcinoma Progression.

Authors:  Luca Fabris; Keisaku Sato; Gianfranco Alpini; Mario Strazzabosco
Journal:  Hepatology       Date:  2020-11-06       Impact factor: 17.298

Review 3.  Prognostic and Predictive Molecular Markers in Cholangiocarcinoma.

Authors:  Sandra Pavicevic; Sophie Reichelt; Deniz Uluk; Isabella Lurje; Cornelius Engelmann; Dominik P Modest; Uwe Pelzer; Felix Krenzien; Nathanael Raschzok; Christian Benzing; Igor M Sauer; Sebastian Stintzing; Frank Tacke; Wenzel Schöning; Moritz Schmelzle; Johann Pratschke; Georg Lurje
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

4.  Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma.

Authors:  Guohe Song; Yang Shi; Lu Meng; Jiaqiang Ma; Siyuan Huang; Juan Zhang; Yingcheng Wu; Jiaxin Li; Youpei Lin; Shuaixi Yang; Dongning Rao; Yifei Cheng; Jian Lin; Shuyi Ji; Yuming Liu; Shan Jiang; Xiaoliang Wang; Shu Zhang; Aiwu Ke; Xiaoying Wang; Ya Cao; Yuan Ji; Jian Zhou; Jia Fan; Xiaoming Zhang; Ruibin Xi; Qiang Gao
Journal:  Nat Commun       Date:  2022-03-28       Impact factor: 17.694

5.  Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma.

Authors:  Cheng Zhou; Xin Zhang; Kaiqian Zhou; Yingyong Hou; Feiyu Chen; Xiangyu Zhang; Yuan Ji; Shuangjian Qiu; Jia Fan; Jian Zhou; Yuhong Zhou; Zheng Wang
Journal:  Ann Transl Med       Date:  2022-04

Review 6.  The Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages.

Authors:  Yuying Tan; Lei Zhao; Yong-Guang Yang; Wentao Liu
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

Review 7.  Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.

Authors:  Gianluca Rompianesi; Marcello Di Martino; Alex Gordon-Weeks; Roberto Montalti; Roberto Troisi
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

Review 8.  Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know.

Authors:  Jacek Baj; Łukasz Bryliński; Filip Woliński; Michał Granat; Katarzyna Kostelecka; Piotr Duda; Jolanta Flieger; Grzegorz Teresiński; Grzegorz Buszewicz; Marzena Furtak-Niczyporuk; Piero Portincasa
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.